Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 4

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 4
---
 read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you
in the section of this prospectus entitled “Where You Can Find More Information.”

On November 10, 2022, we
consummated the business combination (the “Business Combination”) pursuant to that certain Agreement and Plan of Merger, dated as of March 17, 2022 (as amended, restated or supplemented from time to time, including by Amendment
No. 1 to Agreement and Plan of Merger, dated as of September 12, 2022) (the “Merger Agreement”), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the “Merger Sub”), and the pre-Business Combination Scilex Holding Company (“Legacy Scilex”). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised) and a
domestication under Section 388 of the Delaware General Corporation Law, as amended (the “DGCL”), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the
“Domestication”), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the “Merger”), with Legacy Scilex surviving as
our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company.

On September 21, 2023, we entered into, and consummated the transactions contemplated by the Scilex-Oramed SPA. Pursuant to the
Scilex-Oramed SPA, among other things, on September 21, 2023, we (i) issued to Oramed (A) the Oramed Note due 18 months from the date of issuance in the principal amount of $101,875,000, and (B) the Penny Warrant to purchase up
to an aggregate of 13,000,000 shares of Common Stock, with an exercise price of $0.01 per share and restrictions on exercisability (as more fully described elsewhere in this prospectus), and (ii) caused the Transferred Warrants to purchase up
to an aggregate of 114,286 shares of